Navigation Links
Kidneys for Transplant Function Earlier and Last Longer When Preserved in a Machine Compared to the Traditional Box of Ice

GRONINGEN, The Netherlands, Dec. 31 /PRNewswire/ -- Results from a landmark trial published today in the New England Journal of Medicine, show that in transplanted kidneys preserved and transported in a specially designed machine (LifePort Kidney Transporter) the odds for experiencing a delay in recovery of kidney function are 43% lower, and that these kidneys are 48% less likely to fail within a year compared to those stored in the traditional box of ice (cold storage).(1) The study was the first randomised, prospective trial to compare these two methods of preservation.

Depending on the type of deceased donor,* 15¿50 percent of transplanted kidneys do not function immediately following transplantation and many patients will require dialysis treatments for a certain period after transplantation.(2,3,4) As a result, these kidneys have an increased risk of rejection (3) and survival of the kidney graft may be compromised. This in turn will put pressure on the already long transplant waiting lists.(3,4)

"This is a truly important finding for the thousands of people on transplant waiting lists around the world", said Rutger Ploeg, coordinating principal investigator for the trial and Professor of Transplant Surgery at the University Medical Center Groningen, The Netherlands. "The ongoing challenges we face today are a global shortage of organs for transplantation and that a growing number of the organs available for transplantation are often from older donors or from people with more complex medical conditions. Evidence tells us that these kidneys may not work as well immediately post transplantation and as a result may not last as long. This trial shows us that, regardless of the type of donor, by using machine preservation we can ensure that there will be more kidneys available for transplantation and that they will be in better health."

Cyril Moers, lead author and clinical research trainee at the University Medical Center Groningen, added "The results of the study clearly show the advantages of machine preservation over the traditional box of ice. Although machine preservation has been around for quite some decades, a large randomised clinical trial investigating its merits had never been conducted. Our international study for the first time demonstrates that any deceased donor kidney will benefit from this preservation method."

Facts about the trial

  • The Machine Preservation Trial was an investigator-driven study, run by an independent scientific steering committee across The Netherlands, Belgium and the German federal state of North Rhine Westphalia, in close collaboration with Eurotransplant International Foundation (the international organ exchange organisation for Austria, Belgium, Croatia, Germany, Luxemburg, The Netherlands and Slovenia) as the central trial assistance desk. Principal investigators were Rutger Ploeg (Groningen, The Netherlands), Andreas Paul (Essen, Germany), and Jacques Pirenne (Leuven, Belgium).
  • During the time of the trial, every deceased donor in the area was considered for inclusion in the study. 336 pairs of kidneys were enrolled in the study. One kidney from each pair was randomly assigned to machine preservation, and the other one to cold storage. Kidneys were transplanted in recipients across the Eurotransplant area.
  • The manufacturers, Organ Recovery Systems of Chicago, USA provided the LifePort Kidney Transporters used in the study. The machines were used for the preservation and transport of kidneys from organ recovery until transplantation.

Study Endpoints

  • The primary endpoint was delayed graft function defined as the need for dialysis in the first week post transplantation. Evidence suggests that organs that do not function immediately after transplantation have an increased risk of rejection and survival of the transplanted kidney may be inferior.(2)
  • Secondary endpoints included: patient and graft survival up to 12 months after transplantation, duration of delayed graft function, length of stay in hospital, primary non-function of the transplanted kidney, serum creatinine and clearance after transplantation, acute rejection and calcineurin inhibitor toxicity.

Results from the study

  • Machine perfusion significantly reduced the risk of delayed graft function compared to cold storage. 70 out of 336 kidney recipients in the machine perfusion group developed delayed graft function compared with 89 out of 336 patients in the cold storage group (adjusted odds ratio 0.57; P=0.01).
  • In case delayed graft function occurred, its duration was shorter after machine perfusion compared with cold storage (10 days vs. 13 days; P=0.03).
  • One year graft survival was superior in the machine perfusion group (94% vs. 90%; P=0.04) and machine perfusion was associated with a reduced risk of graft failure in the first year post-transplant (hazard ratio 0.52; P=0.03).
  • Serum creatinine values were significantly lower for machine perfused kidney recipients compared to those cold stored in the first two weeks post transplantation (P=0.01).
  • There were no significant differences observed for the other secondary endpoints.
  • No serious adverse events were directly attributable to machine perfusion.

Facts about transplantation

  • More than 1.5 million people worldwide suffer from end stage renal disease.(5)
  • In the USA alone, for example, there are currently 82,435 people waiting for a kidney transplant. To date this year 4,213 kidneys have been recovered from deceased donors.(6)
  • Eurotransplant International Foundation (Eurotransplant) is the international organ exchange organisation for Austria, Belgium, Croatia, Germany, Luxemburg, The Netherlands and Slovenia and serves a population of 118 million.
  • In the Eurotransplant area there are currently 10,719 people waiting for a kidney transplant (active waiting list of September 30, 2008).(7)
  • In 2007, 3,420 people received a kidney transplant in the Eurotransplant region.(7)

Notes to editors:

* Deceased donors include:

  • Brain dead donors - patients who meet the legal and medical criteria for brain stem death, whose organs are removed for transplantation.
  • Donors after cardiac death (DCD) - organ donors who have been declared dead because their heart has stopped (also called non-heart-beating donors).
  • Expanded criteria donors (ECD) - brain dead donors or donors after cardiac death over the age of 60 years, or between 50 and 60 years with additional health conditions such as high blood pressure, stroke, or a sub-optimal kidney function prior to organ retrieval.

    Trial organisational structure
    Scientific steering committee
    Rutger J. Ploeg (coordination principal investigator, The Netherlands)
    Andreas Paul (principal investigator, North Rhine Westphalia, Germany)
    Jacques Pirenne (principal investigator, Belgium)
    Cyril Moers (secretary)
    Mark-Hugo Maathuis (regional perfusion center liaison)
    Jaap Homan van der Heide (member)
    Ernst van Heurn (member)
    Jean-Paul Squifflet (member)
    Jurgen Treckmann (member)

    Central trial assistance
    Arie Oosterlee (Eurotransplant, general director)
    Axel Rahmel (Eurotransplant, medical director)
    Jacqueline Smits (Eurotransplant, statistician)
    Margitta van Kasterop-Kutz (Eurotransplant, data manager)
    Gunter Kirste (Deutsche Stiftung Organtransplantation, general director)
    Ulrike Wirges (Deutsche Stiftung Organtransplantation, director North Rhine Westphalia)

    Regional perfusion center coordinators
    Henri Leuvenink (Groningen, The Netherlands)
    Frank van Gelder (Leuven, Belgium)
    Bogdan Napieralski (Essen, Germany)

(1) Moers C, Smits JM, Maathuis M-HJ et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 2009;360:7-19.

(2) Koning OH, Ploeg RJ, van Bockel JH et al. Risk factor for delayed graft function in cadaveric kidney transplantation: a prospective study of renal function and graft survival after preservation with University of Wisconsin solution in multi-organ-donors. European Multicenter Study Group. Transplantation. 1997 Jun 15;63(11):1620-8.

(3) Daly PJA, Power RE, Healy DA et al. Delayed graft function: a dilemma in renal transplantation. BJU International 2005;96:498-501.

(4) Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet 2004; 364: 1814.




SOURCE Mechanical Perfusion Study Scientific Steering Committee
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CORD:USE Cord Blood Bank is Proud to Announce that Cord Blood Pioneer and Leading Transplanter Dr. Eliane Gluckman has Joined its Team
2. Stem Cell Transplantation Program at Hackensack University Medical Center: First in Nation to Receive Joint Commission Certification for Quality and First in New Jersey to be Named a Blue Distinction(R) Center for Specialty Care.
3. AST Endorses Istanbul Declaration to End Organ Trafficking and Transplant Tourism
4. The First Ever Transplantation World-Wide of Entire Arms at the "Klinikum rechts der Isar" in Munich
5. Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop Designer Transplants
6. Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkins Lymphoma
7. Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
8. Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection
9. New Independent Research Study Indicates That Cylexs ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection
10. Transplanted cells may hold the key to curing hemophilia A, Einstein scientists report
11. Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program
Post Your Comments:
(Date:11/24/2015)... ... , ... This fall, global software solutions leader SAP and AdVenture Capital brought ... pitch their BIG ideas to improve health and wellness in their schools. , Now, ... the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl 50, ...
(Date:11/24/2015)... SHPG ) announced today that Jeff Poulton , Chief ... Annual Healthcare Conference in New York City , ... p.m. GMT). --> SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> Shire plc ...
(Date:11/24/2015)... 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual ... 11:00 a.m. Israel time, at the law offices ... Street, 36 th Floor, Tel Aviv, Israel . ... and Izhak Tamir to the Board of Directors; , ... , approval of an amendment to certain terms of options granted ...
(Date:11/24/2015)... SAN FRANCISCO , Nov. 24, 2015 /PRNewswire/ ... today announced that Emily Leproust, Ph.D., Twist Bioscience ... Piper Jaffray Healthcare Conference on December 1, 2015 ... Palace Hotel in New York City. ... . Twist Bioscience is on ...
Breaking Biology Technology:
(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has ... of MIT and Harvard for use of its ... information management tools. The partnership will support the ... biological and chemical research information internally and with ... be used for managing the Institute,s electronic laboratory ...
Breaking Biology News(10 mins):